Clinical trial demonstrates safety of new approach to treat invasive kidney cancer
A new approach using precisely targeted, high-dose radiation to treat invasive kidney cancer proves safe, based on a clinical trial by the UT Southwestern Harold C. Simmons Comprehensive Cancer Center s kidney cancer program. The study, published in the
International Journal of Radiation Oncology Biology Physics, could offer new hope for patients with a historically dismal condition.
Among the top 10 cancers in the U.S., most kidney cancers are renal cell carcinoma (RCC). While many cases are caught early, in about 30 percent of patients RCC has invaded or spread at the time of diagnosis. Kidney cancers have the uncanny ability to penetrate draining blood vessels, which become channels for their growth and expansion.
Share this article
Share this article
SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the TomoTherapy
® System. The study, published online in the
International Journal of Radiation Oncology Biology Physics, also reported that the once-daily schedule was associated with a very low incidence of acute and late toxicities.
The TomoTherapy platform, including the next-generation Radixact
® System, is the first in the world capable of helical radiation delivery. Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivering from a full 360 degrees around the patient as the treatment table also moves at a deliberate pace, providing greater control of the radiation dose so it